Danaher Corporation $DHR Shares Sold by Alpha Family Trust

by · The Cerbat Gem

Alpha Family Trust trimmed its holdings in shares of Danaher Corporation (NYSE:DHR – Free Report) by 27.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,200 shares of the conglomerate’s stock after selling 460 shares during the quarter. Alpha Family Trust’s holdings in Danaher were worth $246,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Nuveen LLC acquired a new stake in shares of Danaher in the first quarter valued at about $833,941,000. GAMMA Investing LLC lifted its stake in Danaher by 24,958.2% in the 1st quarter. GAMMA Investing LLC now owns 1,870,847 shares of the conglomerate’s stock valued at $383,524,000 after buying an additional 1,863,381 shares in the last quarter. Two Sigma Advisers LP boosted its holdings in Danaher by 4,248.8% in the 4th quarter. Two Sigma Advisers LP now owns 1,639,500 shares of the conglomerate’s stock worth $376,347,000 after buying an additional 1,601,800 shares during the last quarter. Invesco Ltd. increased its stake in Danaher by 44.5% during the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate’s stock worth $965,259,000 after buying an additional 1,450,703 shares in the last quarter. Finally, Point72 Asset Management L.P. increased its stake in Danaher by 460.6% during the 4th quarter. Point72 Asset Management L.P. now owns 1,348,544 shares of the conglomerate’s stock worth $309,558,000 after buying an additional 1,107,998 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Up 0.3%

Shares of NYSE DHR opened at $210.84 on Monday. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32. The business’s 50 day moving average is $199.94 and its two-hundred day moving average is $199.54. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $279.90. The firm has a market cap of $150.97 billion, a price-to-earnings ratio of 44.86, a PEG ratio of 2.94 and a beta of 0.73.

Danaher (NYSE:DHR – Get Free Report) last posted its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.64 by $0.16. The firm had revenue of $5.94 billion for the quarter, compared to the consensus estimate of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%. The company’s quarterly revenue was up 3.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.72 EPS. Research analysts predict that Danaher Corporation will post 7.63 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. TD Cowen lifted their price target on Danaher from $240.00 to $248.00 and gave the stock a “buy” rating in a research note on Wednesday, April 23rd. Wall Street Zen raised shares of Danaher from a “hold” rating to a “buy” rating in a research note on Friday, June 27th. Robert W. Baird increased their target price on shares of Danaher from $225.00 to $226.00 and gave the company an “outperform” rating in a research report on Friday, July 18th. Evercore ISI lowered their price target on shares of Danaher from $230.00 to $226.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 8th. Finally, JPMorgan Chase & Co. cut their price objective on shares of Danaher from $280.00 to $260.00 and set an “overweight” rating for the company in a report on Tuesday, April 22nd. Three research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $247.61.

Read Our Latest Report on Danaher

Danaher Company Profile

(Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Further Reading